Herceptin for HER2-positive breast cancer improves long-term survival

December 16, 2014 9:07 AM

3 0

Herceptin for HER2-positive breast cancer improves long-term survival

The study, published in the Journal of Clinical Oncology, analyzed data from two independent trials designed to examine overall survival of patients with early-stage HER2-positive breast cancer who received chemotherapy with and without Herceptin.

The authors note that over 4,000 patients with HER2-positive operable breast cancer were enrolled and given "doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in both trials."

Read more

To category page

Loading...